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Little is known about the migration of bacteriocins across human cells. in this study, we report on 
migration of three bacteriocins nisin, plantaricin 423 and bacST4SA across colonic adenocarcinoma 
(Caco-2) cells and human umbilical vein endothelial cells (HUVECs). Bacteriocins were fluorescently 
labelled while still maintaining antimicrobial activity. Migration of fluorescently labelled bacteriocins 
across monolayers was assessed in vitro using transmigration well inserts. After 3 h, 75% of nisin, 85% 
of plantaricin 423 and 82% of bacST4SA migrated across the Caco-2 cell monolayer. Over the same 
time span, 88% nisin, 93% plantaricin 423 and 91% bacST4SA migrated across the HUVEC monolayer. 
The viability of both cell types remained unchanged when exposed to 50 µM of nisin, plantaricin 423 
or bacST4SA. The effect of human plasma on bacteriocin activity was also assessed. Activity loss was 
dependent on bacteriocin type and concentration, with the class-iia bacteriocins retaining more activity 
compared to nisin. This is the first report of bacteriocins migrating across simulated gastrointestinal- 
and vascular-barriers. This study provides some of the first evidence that bacteriocins are capable of 
crossing the gut-blood-barrier. However, in vivo studies need to be performed to confirm these findings 
and expand on the role of bacteriocin migration across cell barriers.
Several studies have shown the tremendous benefits of probiotics, which are defined as health-promoting bacte-
ria1–4. Lactic acid bacteria belonging to the genera Lactobacillus and Bifidobacterium are most frequently used as 
probiotics2,3. Many of these strains produce antimicrobial compounds, including bacteriocins, which may assist in 
the control of gastrointestinal infections5. Studies using human intestinal epithelial cells and mice have suggested 
that probiotics may also play a role in maintaining the integrity of the gut-blood barrier (GBB)6,7. However, little 
is known about the migration of bacteriocins across gastrointestinal epithelial and vascular endothelial cells7.
Experiments conducted on mice have shown that bacteriocins may have beneficial therapeutic properties 
in vivo. Corr et al. (2007) demonstrated that the probiotic strain, Lactobacillus salivarius UCC118, produces a 
bacteriocin (Abp118) in vivo that protects mice against infection with Listeria monocytogenes EGDe8. Nisin F 
suppressed the growth of Staphylococcus aureus in the peritoneal cavity for at least 15 minutes9. However, biolu-
minescence revealed the re-emergence of S. aureus after 44 hours, suggesting that nisin F was degraded by prote-
olytic enzymes or inactivated by non-specific binding9. In another study, Brand and co-workers (2011) showed 
that intraperitoneal administration is an optimal route for treatment with bacteriocins. An immediate decrease in 
infection was observed after nisin F was injected into mice infected with L. monocytogenes EGDe and S. aureus10. 
Moreover, nisin F may have a stabilizing effect on the microbiota, since the bacterial population in the gastrointes-
tinal tract (GIT) of mice remained relatively unchanged after nisin F was administered intraperitoneally11. Nisin 
and other bacteriocins have also been shown to have immune modulatory properties12,13.
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Nisin A, a lantibiotic produced by Lactococcus lactis subsp. lactis, is active against a number of Gram-positive 
bacteria, including Listeria, Staphylococcus, Bacillus and Clostridium spp.14–16. Nisin is one of the most studied 
bacteriocins, has GRAS (generally regarded as safe) status and is commercially available as Nisaplin®, which is 
used as a food preservative17,18. Nisin binds to lipid II in the bacterial cell wall and prevents cell wall biosynthesis, 
or forms pores in the cell membrane, leading to depolarization of the cytoplasmic membrane and the efflux of cell 
components, resulting in cell death19. Nisin has also been shown to have immune modulatory properties superior 
to that of the human cationic peptide LL-3713.
The probiotic properties of Lactobacillus plantarum 423 and Enterococcus mundtii ST4SA have been well stud-
ied20–28. Lactobacillus plantarum 423 adheres to the small intestine of the GIT and E. mundtii ST4SA to the lower 
part of the GIT24, preventing gastrointestinal pathogens such as L. monocytogenes from attaching to the GIT20,23,28. 
In vivo bioluminescence studies conducted on mice28 have shown that L. plantarum 423 and E. mundtii ST4SA, 
colonise the GIT and prevent L. monocytogenes EGDe from causing systemic infections.
Plantaricin 423 (producer: L. plantarum 423) is a class IIa bacteriocin, active against a variety of Gram-positive 
bacteria, including opportunistic pathogens such as L. monocytogenes and Enterococcus faecalis19–25,27–29. 
BacST4SA (producer: E. mundtii ST4SA), also classified as a class IIa bacteriocin, is active against L. monocy-
togenes, S. aureus and E. faecalis21,30. Both bacteriocins bind to target cells by means of electrostatic interactions 
between positively charged amino acids and negatively charged phospholipids in the cytoplasmic membrane29,31.
Bacteriocins with bactericidal properties, such as those mentioned above, may serve as an alternative to anti-
biotics and could eradicate a number of bacterial infections, including infections caused by multidrug-resistant 
strains32. Bacteriocins are bactericidal at low (nanomolar) concentrations (in vitro) and are not toxic to humans 
when administered at MIC (minimum inhibitory concentration) levels7,33,34. Furthermore, since bacteriocins 
are ribosomally encoded, genes involved in the production of the mature (active) peptide can be identified and 
cloned for heterologous production, or the producer strain may be genetically engineered to increase the yield35,36.
Drugs administered orally not only need to withstand harsh conditions of the GIT, but also need to cross the 
highly selective gastro-intestinal epithelial and vascular endothelial cells of the GBB in order to enter the blood 
stream7. Bacteriocins are labile to degradation by proteolytic enzymes in the GIT and are unstable in chem-
ically complex environments such as blood36,37. The proteolytic stabilities of therapeutic compounds vary in 
serum, plasma and fresh blood, because the composition of proteases differs between these blood components38. 
Different proteases recognise different cleavage sites. In blood coagulation, serine proteases are mostly involved, 
thus cleaving C-terminal lysine or arginine. These proteases also degrade peptides that contain basic residues, 
such as positively charged histidine. Importantly, peptides can also bind to blood cells and plasma proteins39. 
Therefore, for bacteriocins to be a vaible treatment option they would need to be encapsulated in protective nan-
oparticles to overcome in vivo degradation. Another option is to use probiotic bacteria (encapsulated if needed) 
as delivery vehicles to constantly secrete bacteriocins in the GIT1,25. With recent developments in nanotechnol-
ogy40–42, and the latest knowledge gained on the expression of genes coding for bacteriocin production and secre-
tion26,31,35,43–45, target-specific delivery of bacteriocins could soon become a reality. However, apart from limited 
reports46,47, little research has focused on the pharmacodynamics of bacteriocins and not much is known about 
the migration of these peptides across gut epithelial or vascular endothelial layers7.
Mechanisms associated with barrier selectivity are not fully understood. Molecular size and physiochemical 
properties of substances may play a crucial role48. The hydrophobicity of bacteriocins suggests they may interact 
with epithelial cells in the GIT, but this could also lead to undesired cytotoxicity. Moreover, because of the small 
size of bacteriocins, they may have the ability to migrate across barriers paracellularly. Human colonic adeno-
carcinoma (Caco-2) cells are normally used in drug transport studies, since intestinal absorption may determine 
the clinical success or failure of a therapeutic agent49. Human umbilical vein endothelial cells (HUVEC) are 
enzymatically removed from human umbilical veins and are commonly used in in vitro studies, especially in 
inflammation studies.
The purpose of this study was thus firstly to produce, purify and characterise selected bacteriocins, and sec-
ondly, to assess the capacity of these active bacteriocins to migrate across epithelial/endothelial barriers. We 
describe the use of Caco-2 and HUVEC monolayers in a Transwell system, to simulate the epithelial and vascular 
endothelial barriers in the GBB and to study the migration capacity of nisin A, plantaricin 423 and bacST4SA in 
this context (Fig. 1). We also report on risk for cytotoxic effect of these peptides in the two cell lines. Additionally, 
stability of the three bacteriocins was monitored in human plasma.
Results
Bacteriocins nisin A, Plantaricin 423 and BacST4SA were characterised for various properties relevant to their 
potential for in vivo therapeutic effect – these included MIC, stability in plasma and risk of cytotoxicity.
MIC levels of Nisin A, Plantaricin 423 and BacST4SA. The MIC levels of nisin A, plantaricin 423 and 
bacST4SA were 8 µM, 12 µM and 10 µM, respectively, as determined against L. monocytogenes EGDe.
Stability in plasma. Bacteriocins produced by gut bacteria and able to cross the GBB would enter the cir-
culatory system and as such come into contact with host blood plasma. Thus, in order to have any significant 
systemic bioactivity and benefit, these peptides would have to be stable in plasma. We therefore investigated 
bacteriocin stability in terms of antimicrobial activity, when incubated with various concentrations of plasma. 
After 3 days of incubation in the presence of 40% (v/v) plasma, the antimicrobial activity of 25 µM, 50 µM and 
100 µM nisin A decreased by 79%, 40% and 26%, respectively (Fig. 2). After 3 days in the presence of 80% plasma, 
nisin A (25 µM) lost all of its activity. Higher concentrations of nisin A (50 µM and 100 µM) were slightly more 
stable in the presence of 80% plasma, as shown by a respective 93% and 33% loss in activity. After 3 days of incu-
bation in the presence of 40% plasma, the antimicrobial activity of 25 µM, 50 µM and 100 µM plantaricin 423 
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decreased with 40%, 30% and 17%, respectively. In the presence of 80% plasma the activity of 25 µM, 50 µM and 
100 µM plantaricin 423 declined with 60%, 39% and 29%, respectively. A similar trend in the decline of activity 
was recorded for bacST4SA. After 3 days of incubation in the presence of 40% plasma, the antimicrobial activity 
of 25 µM, 50 µM and 100 µM bacST4SA decreased with 39%, 24% and 16%, respectively. In the presence of 80% 
plasma an activity decrease of 50%, 36% and 22% was observed for 25 µM, 50 µM and 100 µM bacST4SA, respec-
tively. Statistical differences were observed for various days within the different groups (Fig. 2).
cell viability and cytotoxicity of bacteriocins. In addition to plasma stability, bacteriocins crossing 
the GBB should not have a detrimental effect on the host, to prevent potentially harmful or undesired effects, 
such as the instigation of an inflammatory response. In order to investigate the toxicity of bacteriocins to host 
barrier cells, we evaluated their toxicity against endo- and epithelial cells using three different assays. Results 
obtained with XTT and neutral red assays showed no significant difference in percentage viability of both cell 
types after treatment with 25 µM and 50 µM of the three respective bacteriocins (Figs 3 and 4). However, 100 µM 
nisin A, plantaricin 423 and bacST4SA caused a slight reduction in Caco-2 and HUVEC cell viability. Based on 
the LDH release from the two cell lines, the relative cytotoxicity of the peptides was significant when compared to 
the positive control at all three concentrations (Fig. 5). The cytotoxicity levels of 100 µM nisin A, plantaricin 423 
and bacST4SA were 41%, 21% and 12% against HUVEC and 29%, 17% and 14% against Caco-2 cells, respectively. 
Thus, according to the LDH assay nisin A displayed significantly higher levels of cytotoxicity compared to plan-
taricin 423 and bacST4SA. All three peptides were more toxic to HUVEC than Caco-2 cells, as the overall relative 
viability of the cells was lower after treatments during the XTT and neutral red assays. In addition, the relative 
cytotoxicity as assessed by the LDH release assay, increased in a peptide dose-dependent manner. Significant 
differences were also observed between and within treatment groups (Figs 3–5).
Having established significant antimicrobial action, acceptable plasma stability and a relatively low risk for 
cytotoxicity, the capacity of the selected bacteriocins to cross gut epithelial and blood vessel endothelial layers 
was evaluated.
peptide labelling. To facilitate effective visualisation and quantification of peptide migration across endo- 
and epithelial barriers, NHS-fluorescein labelling was used. This technique has previously been shown to have 
minimal effect on the bioactivity of peptides (namely nisin and vancomycin)50. Nisin A, plantaricin 423 and 
bacST4SA were successfully labelled with NHS-fluorescein, as shown by clear fluorescent zones on agar seeded 
with L. monocytogenes EGDe (not shown). The labelled peptides were, however, less active than the unlabelled 
peptides, as measured by a decrease in activity (determined by antimicrobial zone sizes) of 32%, 24%, 21% for 
nisin A, plantaricin 423 and bacST4SA, respectively.
Migration of bacteriocins across gastrointestinal epithelial cells and vascular endothelial 
cells. To our knowledge, this is the first study reporting on the ability of bacteriocins to cross the GBB. In order 
to evaluate migration of bacteriocins across endo- and epithelial cells, a primary 2D monolayer Transwell migra-
tion model was used. This model is regularly used in pharmacokinetic studies to assess uptake of pharmaceuticals 
from the gut51,52. Migration of nisin A, plantaricin 423 and bacST4SA across Caco-2 and HUVEC cells is shown 
in Fig. 6. After 3 h of incubation, 75% of nisin A, 85% of plantaricin 423 and 82% of bacST4SA migrated across 
the Caco-2 cell monolayer. Migration across HUVEC cells was more rapid, with 88% nisin A, 93% plantaricin 423 
and 91% bacST4SA migrating across the monolayer after 3 h. After 3 h similar results were recorded for residual 
peptide remaining in inserts, compared to the control (no monolayer). The percentage attached and/or entered 
peptide was calculated; 21% nisin A, 11% plantaricin 423 and 12% bacST4SA remained attached to Caco-2 cells. 
In the case of HUVECs, 6% nisin A, 0% plantaricin 423 and 3% bacST4SA remained attached or entered the 
cells (Fig. 7). None of the labelled peptides were cytotoxic to any of the two cell lines, as indicated by trypan blue 
staining (not shown).
Figure 1. Simulated gastrointestinal epithelial/vascular endothelial barrier constructed with Caco-2 and 
HUVEC cells, respectively. Transmigration inserts (8 µm pore size) on which the cell lines have been cultured 
were inserted into wells of a 24-well plate. Figure created in BioRender (https://biorender.io/).
4Scientific RepoRtS |         (2019) 9:11481  | https://doi.org/10.1038/s41598-019-47843-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 2. Effect of human blood plasma on the antimicrobial activity of nisin A, plantaricin 423 and bacST4SA 
over three days. Changes in the antimicrobial activity against L. monocytogenes EGDe were observed by 
spotting the peptides on agar plates and measuring the inhibition zones. Antimicrobial activity of the peptides 
in the presence of 0% plasma (blue), 40% plasma (red) and 80% plasma (grey) are represented as zone diameter. 
Statistical differences (p < 0.05) are indicated by symbols above data points (*Differences between all plasma 
concentrations, **Differences between 0% and 40%, θdifferences between 0% and 80%, φDifferences between 
40% and 80%).
Figure 3. The effect of nisin A (blue), plantaricin 423 (red) and bacST4SA (grey) on cell viability, as recorded 
using the XTT assay. (A) Cell viability of Caco-2. (B) Cell viability of HUVECs. Viability after treatment with 
25 µM, 50 µM and 100 µM of the peptides are represented as a percentage of total cell viability. Sterile ultrapure 
water was used as negative control (green) and represents 100% cell viability. Significantly different values are 
indicated (p < 0.05) above bars with lines and * indicates significant difference with the control.
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Discussion
Recently we proposed the possibility of bacteriocins crossing the GBB and hypothesized on their possible role if 
they do cross7. The results in this study provide evidence that bacteriocins are indeed capable, at least in vitro, to 
cross the GBB. Additionally, we also provide data for the bioavailability of these peptides when in contact with 
human serum. These results provide a framework for future studies to establish the exact mechanism of bacteri-
ocin GBB crossing and justification for future in vivo studies.
Since most bacteriocins are membrane active and are hydrophobic, they may attach to cells or other proteins, 
limiting their availability10,22. Furthermore, due to their proteinaceous nature they are also liable to degradation 
by proteolytic enzymes. In a study by Brand et al., 2010, S. aureus Xen 36-infected mice were treated with nisin 
F, which is similar to nisin A used in this study9. Nisin F was administered intraperitoneally at a concentration of 
640 AU (arbitrary units). Nisin F suppressed the growth of S. aureus Xen 36 in vivo only for the first 15 minutes. 
The authors hypothesized that the re-emergence of S. aureus was due to degradation of nisin F by proteolytic 
enzymes. However, as with nisin A, nisin F contains lanthionine bridges which makes it more resistant to pro-
teolytic degradation. In another study nisin F incorporated into bone cement was able to prevent S. aureus Xen 
36 infection when implanted into an infected subcutaneous pocket53. Nisin A and other lantibiotics have also 
Figure 4. The effect of nisin A (blue), plantaricin 423 (red) and bacST4SA (grey) on cell viability using the 
neutral red assay. (A) Cell viability of Caco-2. (B) Cell viability of HUVECs. Viability after treatment with 
25 µM, 50 µM and 100 µM of the peptides are represented as a percentage of total cell viability. Sterile ultrapure 
water was used as negative control (green) and represents 100% cell viability. Significantly different values are 
indicated (p < 0.05) above bars with lines and * indicates significant difference with the control.
Figure 5. The effect of nisin A (blue), plantaricin 423 (red) and bacST4SA (grey) on plasma membrane integrity 
using the LDH release assay. (A) Cytotoxicity towards Caco-2. (B) Cytotoxicity towards HUVECs. Cytotoxicity 
after treatment with 25 µM, 50 µM and 100 µM of the peptides are represented as a percentage of maximum 
LDH release. Lysis buffer was used as positive control (green) and represents 100% cytotoxicity. Significantly 
different values are indicated (p < 0.05) above bars with lines and all treatment groups are significantly differnt 
to positive control.
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been used to successfully treat and prevent skin infections caused by S. aureus54,55. Therefore, it is possible that 
the concentration of nisin used was not high enough to compensate for non-specific binding of nisin to other 
proteins or membranes. However, peptide removal through immune clearance or proteolytic degradation cannot 
be discounted without further in vivo study. Non-specific binding and/or proteolytic degradation may explain 
the loss in antimicrobial activity observed for nisin A, plantaricin 423 and bacST4SA after prolonged exposure 
(1 to 3 days) to blood plasma. Non-specific binding of bacteriocins in the GIT and the GIT environment may 
also have an effect on the bioactivity of bacteriocins. In the case of antibiotics, delivery to the site of infection is 
usually within 3 h33,56. Chloramphenicol is rapidly absorbed in the GIT when administered orally and reaches 
peak blood levels within 2 hours56. Penicillin G is destroyed by gastric acid and is therefore administered intrave-
nously, whereas penicillin V is more acid-stable with a bioavailability between 60% and 70%. Amoxicillin has an 
even greater oral bioavailability (74% to 92%). Further in vivo experiments are required to determine the optimal 
dosage of bacteriocins, as high dosages may be toxic.
Previous studies have shown that certain AMPs such as melittin, pediocin and colicin E6 have the ability to 
interact with mammalian proteins involved in metabolism, disrupt mitochondrial processes, cell structure and 
cause apoptosis57,58. It is therefore crucial to study the interaction of AMPs with mammalian cells to evaluate their 
potential toxicity before they can be considered for delivery to infectious sites. In the context of the GIT, bacteri-
ocins that are produced by resident- or probiotic-bacteria potentially cross into the circulatory system. Bacteriocin 
toxicity and interaction with mammalian proteins is therefore equally important as these interactions could 
result in detrimental/beneficial host responses. Furthermore, the hydrophobicity of nisin A, plantaricin 423 and 
bacST4SA suggests they may interact with epithelial cells in the GIT and cause undesired toxicity58. In this study, 
nisin A, plantaricin 423 and bacST4SA did not cause significant decreases in HUVEC or Caco-2 cell viability at 
concentrations up to 50 µM in the XTT and neutral red assays. Results from the LDH release assay indicate that 
nisin A, plantaricin 423 and bacST4SA have minimal toxicity against Caco-2 cells and HUVECs at concentrations 
up to 100 µM. These concentrations are, however, well above that required to be effective against sensitive strains 
in vitro. Nisin A, a FDA approved food preservative, displayed significantly higher levels of toxicity compared to 
Figure 6. Ability of nisin A, plantaricin 423 and bacST4SA to migrate across a simulated barrier of 
gastrointestinal epithelial and vascular endothelial cells. (A) Migration of peptides across a Caco-2 cell 
monolayer. (B) Migration of peptides across a HUVEC monolayer. Migrated nisin A (blue), plantaricin 423 
(red) and bacST4SA (grey) is expressed as percentage of total fluorescence. Statistical differences (p < 0.05) are 
indicated by symbols above data points. *Differences between all bacteriocins, **Differences between 423 and 
ST4, #Differences between Nisin and ST4, φDifferences between Nisin and 423.
Figure 7. Representative image of fluorescent peptides that attached to or entered the Caco-2 cells (A) 
and HUVECs (B) after 3 h of incubation. (1) No peptide or fluorescent marker; (2) NHS-fluorescein; (3) 
fluorescently labelled nisin A; (4) fluorescently labelled plantaricin 423; (5) fluorescently labelled bacST4SA.
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plantaricin 423 and bacST4SA in both cell lines. This increase in cytotoxicity could be associated with an increased 
hydrophobicity, however, the mechanisms involved in the different toxicity levels requires further study. The 
overall cytotoxicity of nisin A, plantaricin 423 and bacST4SA was greater against HUVECs compared to Caco-2 
cells. In a study done by Murinda et al. (2003), nisin, pediocin and selected colicins showed different cytotoxicity 
levels amongst colonic cells and Vero (kidney) cells57. These differences may be due to the eukaryotic cell type 
used. However, other explanations include potential presence of impurities in the AMP preparations used, loss of 
activity after purification, different exposure times, solvents or media used58. However, in the current study the 
differences in cytotoxicity levels between HUVECs and Caco-2 cells are likely associated with different cell lines 
used, as the peptides were purified to homogeneity and all solvents were removed. Cytotoxicity studies carried out 
by Maher (2006) showed that approximately 80 µM nisin A did not have a significant cytotoxic effect on Caco-2 
cells58. The current study expands on this report by demonstrating that the cytotoxicity of nisin A, plantaricin 
423 and bacST4SA indeed only increased at concentrations higher than 50 µM. Even though some toxicity was 
observed, this was under optimal conditions with elevated bacteriocin concentrations. Factors such as immune 
inactivation, host clearance mechanisms and other limiting agents, or antagonists, to the bacteriocins were not 
present. In studies done by van Staden et al., (2016) and Heunis et al., (2013) lantibiotics were successfully used to 
treat skin infections without any adverse effects54,55. Even though toxicity was not seen in these studies, future in 
vivo studies should be done to evaluate specific toxicity in the GIT and would provide more information regarding 
the maximum tolerated doses as well as cell type-specific responses to the peptides.
The gastrointestinal barrier is highly selective and prevents the passage of toxic compounds of the luminal 
microflora whilst allowing the absorption of nutrients from the gut lumen59. The molecular size and physiochem-
ical properties of substances play a significant role in this selectivity48. Moreover, the vascular endothelial barrier 
may play a vital role in maintaining the function and structure of the intestinal barrier. Orally administered 
therapeutic agents need to maintain stability throughout the GIT, cross the intestinal mucous layer, the epithe-
lial barrier and the vascular endothelial barrier to reach the blood stream so that they can be transported to the 
site of infection. Oral drug delivery vectors such as probiotics can help protect AMPs during GIT transport for 
effective delivery to infectious sites. Direct oral delivery of nisin A to the site of gastrointestinal colonic infections 
has also been investigated and is currently under patent60. In the current study, a simulation of the gastrointestinal 
epithelial and vascular endothelial barrier was used to determine if bacteriocins can cross these barriers. Since 
bacteriocins are extremely small they may diffuse across these barriers by means of the paracellular pathway. 
Results from this study corroborate this hypothesis. The AMPs, nisin A, plantaricin 423 and bacST4SA can cross a 
simulation of the epithelial and endothelial layers. Moreover, a small amount of the peptides can attach to or enter 
epithelial (Caco-2) cells, and nisin A and bacST4SA can attach to or enter endothelial cells (HUVECs). This study 
did not determine whether the bacteriocins attach to, or enter, the mammalian cells. From our results it is clear 
that the proportion of bacteriocins that enter/attach cells is not significant compared to the amount that cross the 
barriers. However, if the bacteriocins entered cells, through mechanisms such as pinocytosis, they did not result 
in toxicity under the current experimental conditions. Furthermore, the fact that the labelled peptides were not 
cytotoxic suggests that peptide migration across monolayers did not occur due to pore formation or cell death.
Plantaricin 423 is most effective at migrating across these barriers, but is least effective at attaching to or enter-
ing the cells. In contrast, nisin A is the least effective at crossing the barriers but a larger amount of the peptide 
attached to or entered the cells. Migration across monolayers and association of the peptides with HUVECs or 
Caco-2 cells differed. Migration across HUVECs was much more rapid with a substantial drop in the association 
(attachment/entrance) of peptides with HUVECs compared to Caco-2 cells. This could be due to the differences 
of junctions between the two cell types (i.e. endothelial and epithelial), as well as cell morphology. Additionally, 
the differences in the ability of the peptides to migrate across the monolayers and associate with cells can be due 
to differences in hydrophobicity, amino acid composition, or size. However, further investigation is required to 
elucidate the exact mechanisms involved in bacteriocin-mammalian cell interactions.
In conclusion, current data illustrated that nisin A, plantaricin 423 and bacST4SA have no significant cyto-
toxicity at effective antimicrobial doses, that they remain stable in blood plasma at these concentrations and that 
they have the capacity to readily migrate across epithelial and endothelial monolayers. The in vitro model used in 
the current study has limitations and does not fully represent the complex in vivo environment of the GIT. Where 
changes in the structure, function, physiology or pathology of living cells and organs are the focus, organoid 
models would be preferable. Additionally, advanced visualisation techniques such as microfluidic and confocal 
microscopy could shed more light on potential occurrence of cell internalisation of peptides, as well as membrane 
transport mechanisms involved. These results should be followed up by in vivo studies, to further elucidate the 
potential of bacteriocins to cross the GBB under more complex conditions.
Materials and Methods
SepPak C18 columns were from Waters (Massachusetts, USA). Nisaplin® was from Sigma (Sigma-Aldrich, 
Missouri, USA). The bicinchoninic acid (BCA) protein assay was from Pierce Biotechnology (Massachusetts, 
USA). NHS-fluorescein was from Thermo Fisher Scientific (Massachusetts, USA). Cell viability was verified 
using the neutral red assay (Merck). The XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulphenyl)-2H-Tetrazolium-
5-Carboxanilide) assay was from Merck. Lactate dehydrogenase (LDH) was determined using the LDH release 
assay kit (Merck). Human colonic adenocarcinoma (Caco-2) cells, were grown in Dulbecco’s modified Eagle’s 
medium (DMEM, Merck) and human umbilical vein endothelial cells (HUVEC), in endothelial growth medium 
(EGM; Lonza, Bail, Switzerland).
Peptide production and purification. Single colonies of L. plantarum 423 and E. mundtii ST4SA were 
inoculated into 10 mL MRS broth, incubated for 18 h at 37 °C and transferred to 2 L MRS broth. After 18 h of 
incubation at 37 °C, cells were harvested (11 000 × g for 20 min at 4 °C). The pH of the cell-free supernatant was 
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adjusted to 7.0 and heat-treated at 80 °C for 10 min. Bacteriocins were precipitated from the cell-free supernatants 
with 70% saturated ammonium sulphate, as described previously61. Samples were placed on an orbital shaker 
(200 rpm) at 8 °C for 48 h, the precipitate was collected by centrifugation (20 000 × g, 1 h) and resuspended in 
sterile phosphate buffered saline (PBS, pH 7.0). The suspension was heat treated at 80 °C for 15 min to bring pep-
tides into suspension and then freeze-dried. The freeze-dried peptides were dissolved in sterile PBS and added to 
40 g XAD-16 beads, pre-activated with 80% (v/v) isopropanol containing 0.1% (v/v) TFA. After 24 h on an orbital 
shaker, the beads were collected and washed with 30% (v/v) ethanol for 15 min. Hydrophobic peptides were 
eluted from the beads with 70% (v/v) isopropanol containing 0.1% (v/v) TFA. The beads were left in suspension 
for 18 h on an orbital shaker (100 rpm) at 8 °C. The peptides were separated from the beads by filtering through 
a 0.45 µM cellulose acetate filter and the isopropanol removed using rotary evaporation at 65 °C (RotaVapor®, 
Buchi). Peptides were further purified using Sep-Pak C18 reverse phase columns and eluted using 60% (v/v) 
isopropanol containing 0.1% (v/v) TFA. Isopropanol was removed with rotary evaporation, active fractions were 
freeze-dried, and antimicrobial activity was tested by using the agar well diffusion assay54. Nisaplin® was dis-
solved in 25% acetonitrile (v/v) containing 0.1% (v/v) TFA and centrifuged to remove undissolved particles. The 
supernatant was loaded onto a Sep-Pak C18 column and eluted with 40% (v/v) acetonitrile containing 0.1% (v/v) 
TFA. Active fractions were freeze-dried and tested for activity as mentioned previously.
Plantaricin 423 and bactST4SA were further purified by fast protein liquid chromatography (ÄKTA puri-
fier). Samples were dissolved in 10% (v/v) acetonitrile containing 0.1% (v/v) TFA and added to a HiScale Source 
15RPC column (50 × 16 mm, GE Healthcare Life Sciences). Peptides were eluted with an increasing gradient of 
10% (v/v) to 55% (v/v) acetonitrile containing 0.1% (v/v) TFA. Active samples were freeze-dried, dissolved in 
10% (v/v) acetonitrile and loaded onto a Discovery BIO Wide Pore C18 HPLC (high performance liquid chroma-
tography) column (10 µm, 250 × 10 mm). Plantaricin 423 and bacST4SA were eluted in an acetonitrile gradient 
of 25% (v/v) to 60% (v/v) acetonitrile and nisin in an increasing gradient of 10% (v/v) to 60% (v/v) acetonitrile 
containing 0.1% (v/v) TFA. Active peptides were freeze-dried, re-suspended in sterile ultrapure water containing 
0.1% (v/v) TFA and analysed by liquid chromatography-mass spectrometry (LC-MS; Central Analytical Facility, 
Stellenbosch, South Africa).
Determination of Mic. The BCA assay was used according to the manufactures instructions to determine 
the concentration of the peptides. The MIC of the peptides was determined using a microtiter plate. Briefly, L. 
monocytogenes EGDe was inoculated into Listeria enrichment broth (LEB) and incubated overnight at 37 °C. 
The culture was inoculated into fresh LEB and incubated until an OD600 of 0.1 was reached. A series of peptide 
concentrations was prepared and 50 µL of each added per well, followed by the addition of 150 µL culture. The 
controls were ddH2O containing 0.1% (v/v) TFA with 150 µL culture or media. Microtiter plates were incubated 
at 37 °C and OD600 readings were taken at T0, T5 and T18 (hours). The MIC was determined as the lowest peptide 
concentration required to inhibit the growth of L. monocytogenes EGDe after 18 h.
plasma stability assay. Human blood was collected in tubes with potassium and EDTA as anticoagulant, 
centrifuged at 500 × g (10 min, 25 °C) and the plasma collected. Different plasma concentrations (0%, 40% and 
80%, v/v) were prepared by diluting with sterile ultrapure water. Nisin A, plantaricin 423 and bacST4SA, each sus-
pended in sterile ultrapure water, were added to the plasma to final concentrations of 25 µM, 50 µM and 100 µM, 
sterile ultrapure water was used as control. Incubation was at 37 °C for 3 days and bacteriocin activity was tested 
using the agar well diffusion assay. Listeria monocytogenes EGDe was used as target organism. Digital images of 
the plates were taken after incubation and activity quantified by measuring the diameter of the zones using ImageJ 
software (version 1.5; https://imagej.nih.gov/ij/).
cell culture. Caco-2 cells were used between passages 50 and 60 and grown in DMEM. HUVEC were used 
between passages 5 and 15 and grown in complete EGM. Both cell lines were cultured at 37 °C in a humidified 
atmosphere in the presence of 5% CO2. Cell cultures were routinely sub-cultured before reaching confluence.
For viability and cytotoxicity studies, cells were seeded in 96-well flat-bottom culture plates (1 × 104 cells/
well). To determine migration of nisin A, plantaricin 423 and bacST4SA across the gastrointestinal epithelial and 
vascular endothelial barriers, HUVEC and Caco-2 cells were grown on an 8 µm pore size tissue culture insert, as 
shown in Fig. 1. All cell culture experiments were done in triplicate and have been repeated more than three times.
Viability and cytotoxicity assays. XTT assay. Cells were grown in 100 µL of culture medium for 24 h at 
37 °C. The bacteriocins were separately added to the cells at concentrations of 25 µM, 50 µM and 100 µM. Sterile 
ultrapure water was used as control. After 24 h of incubation at 37 °C, the reaction mixture containing PMS 
(N-methyl-dibenzopyrazine-methylsulfate/phenazine methosulphate) and XTT solution, was added to each well 
and incubated for 4 h at 37 °C. Absorbance readings were recorded at 450 nm, using a microtiter plate reader. The 
percentage viability was calculated as AT/AC × 100; where AT is the absorbance of peptide-treated cells and AC is 
the absorbance of control (untreated cells).
Neutral red assay. Cells were treated with different concentrations of the peptides as described for the XTT 
assay. Sterile ultrapure water was used as control. After incubation at 37 °C for 24 h, neutral red solution was 
added to the cells (10% of the culture volume). After 4 h of incubation at 37 °C, the medium was removed by aspi-
ration and the cells were rinsed with neutral red fixative. The fixative was removed, the dye solubilized by adding 
neutral red and the cells were gently stirred for 10 min on a gyratory shaker. Absorbance readings were recorded 
at 540 nm and 690 nm, respectively, using a microtiter plate reader. The percentage viability was calculated as the 
absorbance of treated cells divided by the absorbance of untreated cells (AT/AC × 100).
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LDH release assay. HUVEC and Caco-2 cells were exposed to three different concentrations (25 µM, 50 µM and 
100 µM) nisin A, plantaricin 423 and bacST4SA and the presence of extracellular LDH determined using the LDH 
release assay kit. Sterile ultrapure water was used as negative control (referred to as spontaneous LDH activity) 
and lysis buffer (10X) was used as positive control (referred to as maximum LDH activity). After incubating the 
cultures in the presence of the peptides for 24 h at 37 °C, culture supernatants were pipetted into a 96-well plate. 
Reaction mixture was added to the supernatants and plates were incubated at 25 °C for 30 min. Absorbance was 
measured at 490 nm and 680 nm, respectively. The percentage cytotoxicity was calculated as follows (1):
=
− −
−
×%Cytotoxicity (Compound treated LDH activity) (Spontaneous LDH activity)
Maximum LDH activity Spontaneous LDH activity
100
(1)
Labelling peptides with NHS-fluorescein. HPLC purified stock solutions of nisin A, plantaricin 423 and 
bacST4SA were prepared by dissolving the peptides in sterile ultrapure water. Immediately before conjugating 
NHS-fluorescein to the peptides, a stock solution of NHS-fluorescein was prepared by dissolving 1 mg of reagent in 
100 µL DMF. The amount of NHS-fluorescein to be added to each peptide was calculated using the Eqs (2) and (3):
× × × =mL peptide mg peptide
mL peptide
mmol peptide
mg peptide
15 mmol NHS
mmol peptide
mmol NHS
(2)
×
.
× =
µ µLmmol NHS 473 4 (MW of NHS)
mmol NHS
100 DMF
1 mg
L NHS
(3)
The calculated concentration of NHS-fluorescein was added to the peptides and incubated on ice for 2 h. 
Non-reacted NHS-fluorescein was removed by Sep-Pak C18 column chromatography. Plantaricin 423 and 
bacST4SA were eluted with 60% acetonitrile containing 0.1% TFA and nisin A with 40% acetonitrile containing 
0.1% TFA. Peptides were freeze dried and resuspended in sterile ultrapure water. Concentrations of the labelled 
peptides were determined with the BCA assay and diluted to 50 µM. Labelled peptides were filtered through a 
0.45 µm HVLP membrane and spotted (20 µL) onto LEB agar seeded with 1% L. monocytogenes EGDe (OD600 0.1). 
Plates were incubated overnight at 37 °C and the fluorescent peptides visualised under a UVP 3UV Ultraviolet 
Lamp. Inhibition zones were measured using ImageJ software and compared to those of non-labelled peptides.
Migration of bacteriocins across gastrointestinal epithelial cells and vascular endothelial cells. 
HUVECs and Caco-2 cells were seeded onto transmigration inserts (Fig. 1) at a cell density of 1 × 105 cells/insert 
(200 µL). Inserts were carefully placed in a 24-well tissue culture plate containing 700 µL cell growth media. Cells 
were incubated at 37 °C in a humidified atmosphere in the presence of 5% CO2, until confluency was reached, 
and a monolayer formed. The integrity of the monolayers was monitored by ensuring trans-epithelial electrical 
resistance (TEER) readings remained above 300 Ω throughout the experiment (Millicell-ERS volt-ohm meter, 
Merck)51,52,62. Fluorescently labelled bacteriocins were added to the apical side of the inserts at a concentration 
of 50 µM, respectively. Transmigration inserts containing no monolayer, was used to determine the total fluores-
cence. Samples were incubated for 3 h while absorbance was measured at 490 nm every 30 min using a microplate 
reader. Before each reading, inserts were removed and placed into new microplates containing fresh media. The 
amount of migrated peptide was calculated as a percentage of total fluorescence in wells (without monolayer) (4):
= ×% Migrated peptide Absorbance in well (containing monolayer)
Absorbance in control well (no monolayer)
100
(4)
After 3 h, the absorbance of the residual labelled peptide in the inserts (non-migrated peptide) was measured 
after transferring the non-migrated peptide to 24-well plates containing culture media to a final volume of 700 µl. 
The percentage residual peptide was calculated as a percentage of total fluorescence (5):
− = ×% Residual non migrated peptide Absorbance in insert
Absorbance in control well (no monolayer)
100
(5)
The percentage of peptide that attached to, or entered the cells was quantified by subtracting the sum of 
migrated peptide (eq. 4) and retained peptide (eq. 5) from the total fluorescence. The cells were washed with PBS 
and visulized in the IVIS® 100 In Vivo Imaging System (Caliper Life Sciences, Hopkinton, US)to detect any labelled 
peptide that have attached to, or entered, the cells. To determine the cytotoxicity of NHS-fluorescein labelled pep-
tide, a trypan blue exclusion test63 was performed. Briefly, cells treated for 3 h with labelled bacteriocins were 
harvested by centrifugation as described elsewhere and resuspended in 1 ml PBS. One-part cell suspension (100 μl) 
was added to 100 μl trypan blue (0.4%) and incubated for 3 min at room temperature. The number of unstained 
(viable) and stained (non-viable) cells was determined using a haemocytometer. The percentage viable cells were 
calculated by dividing the total number of viable cells per mL with the total number of cells per ml. The integrity 
of the monolayers was monitored by ensuring TEER readings remained above 300 Ω throughout the experiment.
Statistical analysis. All data were subjected to analysis of variance (ANOVA) followed by Bonferroni’s Multiple 
Comparison Test (p < 0.05). Error bars indicate standard deviation. Data was analysed using GraphPad Prism 
software (version 5.0, USA).
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ethics statement. Exemption was obtained from the research ethics committee of Stellenbosch University 
for the purpose of using human donor blood for in vitro experiments (reference X15/05/013). All subjects donat-
ing blood gave informed consent.
Data Availibility
All data generated or analysed during this study are included in this published article.
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